SLC3A2 and neoplasm: To further investigate the specificity with which the HDAC-inhibitor SAHA selectively modulates tumor cells and whether it incurs any adverse effects in healthy brain tissue, organotypic slice-cultures from healthy rat brains were treated with SAHA and the xCT- and CD98-expressions were analyzed again with real-time RT-PCR.